Insulet Co. (NASDAQ:PODD) Shares Sold by C WorldWide Group Holding A S

C WorldWide Group Holding A S reduced its holdings in Insulet Co. (NASDAQ:PODD) by 11.9% during the 4th quarter, Holdings Channel reports. The firm owned 147,908 shares of the medical instruments supplier’s stock after selling 20,000 shares during the quarter. Insulet makes up about 0.5% of C WorldWide Group Holding A S’s holdings, making the stock its 23rd largest holding. C WorldWide Group Holding A S’s holdings in Insulet were worth $38,614,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the business. Blue Trust Inc. boosted its stake in shares of Insulet by 84.1% in the third quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock worth $30,000 after acquiring an additional 58 shares during the last quarter. Venturi Wealth Management LLC boosted its stake in shares of Insulet by 633.3% in the third quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier’s stock worth $36,000 after acquiring an additional 133 shares during the last quarter. TD Private Client Wealth LLC boosted its stake in shares of Insulet by 32.6% in the third quarter. TD Private Client Wealth LLC now owns 228 shares of the medical instruments supplier’s stock worth $53,000 after acquiring an additional 56 shares during the last quarter. Friedenthal Financial acquired a new stake in shares of Insulet in the fourth quarter worth approximately $57,000. Finally, Versant Capital Management Inc boosted its stake in shares of Insulet by 106.1% in the fourth quarter. Versant Capital Management Inc now owns 305 shares of the medical instruments supplier’s stock worth $80,000 after acquiring an additional 157 shares during the last quarter.

Insulet Price Performance

NASDAQ:PODD opened at $282.80 on Monday. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21. The company has a market capitalization of $19.84 billion, a P/E ratio of 48.84, a P/E/G ratio of 3.62 and a beta of 1.23. Insulet Co. has a 52 week low of $160.19 and a 52 week high of $289.46. The stock’s fifty day moving average is $272.98 and its two-hundred day moving average is $247.87.

Insulet (NASDAQ:PODD) last posted its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.00 by $0.15. The firm had revenue of $597.50 million for the quarter, compared to the consensus estimate of $582.02 million. Insulet had a return on equity of 24.46% and a net margin of 20.19%. Equities analysts expect that Insulet Co. will post 3.92 EPS for the current year.

Insider Activity at Insulet

In other Insulet news, CAO Lauren Budden sold 915 shares of the company’s stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $275.62, for a total transaction of $252,192.30. Following the sale, the chief accounting officer now owns 5,733 shares in the company, valued at $1,580,129.46. This represents a 13.76 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Eric Benjamin sold 12,394 shares of the company’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total value of $3,470,320.00. Following the sale, the executive vice president now owns 11,383 shares in the company, valued at approximately $3,187,240. This trade represents a 52.13 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.47% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have weighed in on PODD. Stifel Nicolaus boosted their price objective on Insulet from $245.00 to $293.00 and gave the stock a “hold” rating in a research note on Friday. Raymond James reissued an “outperform” rating and set a $328.00 price objective (up previously from $294.00) on shares of Insulet in a research note on Friday. TD Cowen boosted their price objective on Insulet from $264.00 to $324.00 and gave the stock a “buy” rating in a research note on Friday, January 3rd. Canaccord Genuity Group boosted their price objective on Insulet from $304.00 to $324.00 and gave the stock a “buy” rating in a research note on Friday. Finally, Piper Sandler boosted their price objective on Insulet from $285.00 to $310.00 and gave the stock an “overweight” rating in a research note on Friday. Three research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $289.06.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.